Okay, thank you Ian. Good afternoon, everybody. Thanks for joining us today. Lets go ahead and jump right in as we have a lot of ground to cover. I think 2018 is a good illustration of how the ...

Amgen, Inc.AMGN has done relatively well in 2018 so far, coming up with strong quarterly results and positive pipeline and regulatory updates. Last month, Amgen reported impressive third-quarter 2018 ...

Amgen CEO Bob Bradway racked up a 2018 pay package of $18.6 million, his first big raise since 2015, thanks to incentive pay that jumped by about $1.2 million. And the company credited sales growth, ...

THOUSAND OAKS, Calif., Oct. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the fourth quarter of 2018. The dividend ...

Amgen, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four ...

In 2015, Amgen gave Kite Pharma $60 million upfront to discover new chimeric antigen receptor T-cell (CAR-T) therapies, which are actually a patient's own immune cells that have been trained offsite ...

THOUSAND OAKS, Calif., Jan. 29, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2018 in comparison to comparable periods in 2017. Key ...

Biogen is best known for its powerhouse multiple sclerosis (MS) franchise. Tecfidera dominates in MS and is on track to generate sales of around $4.2 billion this year. Biogen's interferon products, ...

Amgen forecast that its 2019 earnings and revenue would decline year over year. That news pressured the stock, despite upbeat fourth-quarter results. The company's top two drugs both posted ...

If you're looking to invest in big biotech stocks, two top candidates that you'll probably want to consider are Biogen (NASDAQ: BIIB) and Amgen (NASDAQ: AMGN) . Amgen is by far the larger of the two ...